CHRM4
Muscarinic acetylcholine receptor M4
As of the edition of 20 October 2026, CHRM4 (muscarinic acetylcholine receptor M4, UniProt P08173) has 8 drugs tested at it and 23 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08173
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 39
- Disease areas
- Lungs and airways; Mental health; Skin and connective tissue; Nervous system; Immune system; Digestive system; Infections; Pregnancy and women's health
- Registered trials of its drugs
- 218
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Went quiet | 3 |
| Withdrawn from market | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Glycopyrronium | Marketed | Phase 4 | none listed |
| Xanomeline | Marketed | Phase 4 | none listed |
| Emraclidine | Active | Phase 2 | none listed |
| Darotropium | Went quiet | Phase 2 | none listed |
| Sofpironium | Marketed | Phase 3 | Ends 2040 |
| PT010 | Went quiet | Phase 1 | none listed |
| Afacifenacin | Went quiet | Phase 2 | none listed |
| Terodiline | Withdrawn from market | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 15 |
| Undetermined | 3 |
| Total on the list | 23 |
| Company | Route |
|---|---|
| Botanix Sb | Route B |
| GSK | Route A |
| AstraZeneca | Route B |
The other 20 companies at CHRM4
In the product23 companies in all; 20 are not named here, and no score is.
See the 23 companies at CHRM4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.